@Article{crph1265,
AUTHOR = {Ramakrishnan, Akshay and Rhee, Raju and Lath, Gunjan and Ramakrishnan, Riya},
TITLE = {The Future of Longevity Medicine from the Lens of Digital Therapeutics},
JOURNAL = {Current Research in Public Health},
VOLUME = {5},
YEAR = {2025},
NUMBER = {1},
PAGES = {29-37},
URL = {https://www.scipublications.com/journal/index.php/JAIBD/article/view/1265},
ISSN = {2831-5162},
DOI = {10.31586/jaibd.2025.1265},
ABSTRACT = {Digital therapeutics (DTx) are emerging as a pivotal tool in promoting longevity by addressing non-communicable diseases (NCDs) such as diabetes, cardiovascular diseases, and mental health disorders. These software-driven interventions offer personalized, evidence-based treatments that can be accessed via digital devices, making healthcare more accessible and scalable. One of the key advancements in DTx is the integration of artificial intelligence (AI) and machine learning (ML) to tailor interventions based on individual health data. This personalization enhances the effectiveness of treatments and supports preventive care by identifying risk factors early. The need for digital therapeutics is underscored by the rising prevalence of NCDs, which are responsible for a significant portion of global mortality and healthcare costs. Traditional healthcare systems often struggle to provide timely and personalized care, especially in low-resource settings. DTx can bridge this gap by offering cost-effective solutions that are easily scalable. Moreover, digital therapeutics can address health inequities by providing low-cost interventions to underserved populations, thereby reducing the burden of NCDs and improving overall health outcomes. As technology continues to evolve, the potential for DTx to enhance longevity and quality of life becomes increasingly promising. Recent advancements in longevity medicine and technology have focused on extending both lifespan and healthspan, ensuring that people not only live longer but also maintain good health throughout their extended years. This review article highlights these advancements that are contributing to this compelling subject of Longevity.},
}

%0 Journal Article
%A Ramakrishnan, Akshay
%A Rhee, Raju
%A Lath, Gunjan
%A Ramakrishnan, Riya
%D 2025
%J Current Research in Public Health

%@ 2831-5162
%V 5
%N 1
%P 29-37

%T The Future of Longevity Medicine from the Lens of Digital Therapeutics
%M doi:10.31586/jaibd.2025.1265
%U https://www.scipublications.com/journal/index.php/JAIBD/article/view/1265

TY  - JOUR
AU  - Ramakrishnan, Akshay
AU  - Rhee, Raju
AU  - Lath, Gunjan
AU  - Ramakrishnan, Riya
TI  - The Future of Longevity Medicine from the Lens of Digital Therapeutics
T2  - Current Research in Public Health
PY  - 2025
VL  - 5
IS  - 1
SN  - 2831-5162
SP  - 29
EP  - 37
UR  - https://www.scipublications.com/journal/index.php/JAIBD/article/view/1265
AB  - Digital therapeutics (DTx) are emerging as a pivotal tool in promoting longevity by addressing non-communicable diseases (NCDs) such as diabetes, cardiovascular diseases, and mental health disorders. These software-driven interventions offer personalized, evidence-based treatments that can be accessed via digital devices, making healthcare more accessible and scalable. One of the key advancements in DTx is the integration of artificial intelligence (AI) and machine learning (ML) to tailor interventions based on individual health data. This personalization enhances the effectiveness of treatments and supports preventive care by identifying risk factors early. The need for digital therapeutics is underscored by the rising prevalence of NCDs, which are responsible for a significant portion of global mortality and healthcare costs. Traditional healthcare systems often struggle to provide timely and personalized care, especially in low-resource settings. DTx can bridge this gap by offering cost-effective solutions that are easily scalable. Moreover, digital therapeutics can address health inequities by providing low-cost interventions to underserved populations, thereby reducing the burden of NCDs and improving overall health outcomes. As technology continues to evolve, the potential for DTx to enhance longevity and quality of life becomes increasingly promising. Recent advancements in longevity medicine and technology have focused on extending both lifespan and healthspan, ensuring that people not only live longer but also maintain good health throughout their extended years. This review article highlights these advancements that are contributing to this compelling subject of Longevity.
DO  - The Future of Longevity Medicine from the Lens of Digital Therapeutics
TI  - 10.31586/jaibd.2025.1265
ER  -